CAS: 193079-69-5 - Tabimorelin
Formula:C32H40N4O3
InChI:InChI=1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1
InChI key:InChIKey=WURGZWOTGMLDJP-ZCYANPAGSA-N
SMILES:O=C(C=CCC(N)(C)C)N(C)C(C(=O)N(C)C(C(=O)NC)CC=1C=CC=CC1)CC=2C=CC=3C=CC=CC3C2
- Sinonimi:
- (R)-alpha-((E)-5-Amino-N,5-dimethyl-2-hexenamido)-N-methyl-N-((R)-alpha-(methylcarbamoyl)phenethyl)-2-naphthalenepropionamide
- <span class="text-smallcaps">D</smallcap>-Phenylalaninamide, N-[(2E)-5-amino-5-methyl-1-oxo-2-hexen-1-yl]-N-methyl-3-(2-naphthalenyl)-<smallcap>D</span>-alanyl-N,N<sup>α</sup>-dimethyl-
- <span class="text-smallcaps">D</smallcap>-Phenylalaninamide, N-[(2E)-5-amino-5-methyl-1-oxo-2-hexenyl]-N-methyl-3-(2-naphthalenyl)-<smallcap>D</span>-alanyl-N,N<sup>α</sup>-dimethyl-
- N-[(2E)-5-Amino-5-methyl-1-oxo-2-hexen-1-yl]-N-methyl-3-(2-naphthalenyl)-<span class="text-smallcaps">D</smallcap>-alanyl-N,N<sup>α</sup>-dimethyl-<smallcap>D</span>-phenylalaninamide
- N-[(2E)-5-amino-5-methylhex-2-enoyl]-N-methyl-3-(naphthalen-2-yl)-D-alanyl-N,Nα-dimethyl-D-phenylalaninamide
- Nn 703
- Nnc 26-0703
- Tabimorelin [INN]
- Unii-L51Cbe03Kf
Marchio | Dati del prodotto | Purezza | Fascia di prezzo | Consegna prevista |
---|---|---|---|---|
Tabimorelin REF: 4Z-T-172001CAS: 193079-69-5 | - - - | Prezzo su richiesta | Mar 07 Gen 25 | |
Tabimorelin REF: TR-T003500CAS: 193079-69-5 | - - - | 341,00 €~1.851,00 € | Ven 10 Gen 25 | |
Tabimorelin REF: 3D-THA07969CAS: 193079-69-5 | Min. 95% | Prezzo su richiesta | Mar 11 Feb 25 |
Ref: 4Z-T-172001
10mg | Prezzo su richiesta | ||
25mg | Prezzo su richiesta | ||
50mg | Prezzo su richiesta | ||
100mg | Prezzo su richiesta |
Tabimorelin
Prodotto ControllatoRef: TR-T003500
1mg | 341,00 € | ||
5mg | 1.227,00 € | ||
10mg | 1.851,00 € |
Tabimorelin
Ref: 3D-THA07969
5mg | Prezzo su richiesta | ||
10mg | Prezzo su richiesta | ||
25mg | Prezzo su richiesta | ||
50mg | Prezzo su richiesta |